Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial

Core Insights - Pfizer Inc. is recognized as one of the best affordable stocks under $40, with recent positive results from the BREAKWATER trial for BRAFTOVI in metastatic colorectal cancer patients [1] - The trial demonstrated significant progression-free survival (PFS) improvement and better overall survival, although the latter was a secondary endpoint without statistical backing [2] - Management plans to present detailed results to the FDA for potential approval of the BRAFTOVI regimen [2] Financial Performance - Pfizer reported fiscal Q4 2025 earnings with revenue of $17.6 billion, exceeding estimates by 6%, and earnings per share (EPS) of $0.66, surpassing consensus by 16% [4] - Analysts have mixed views, with some downgrading the stock; for instance, Daiwa downgraded Pfizer from Buy to Hold with a price target of $27, while Bernstein maintained a Hold rating with a price target of $30 [3][4] Company Overview - Pfizer operates as a research-driven global biopharmaceutical company, focusing on developing and commercializing medicines across oncology, primary care, and specialty areas [5]